Lee Financial’s Pacira BioSciences PCRX Stock Holding History

Lee Financial’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-104	Closed	-$6K	–	906
2021 Q4	$6K	Buy	+104	New	+$5.73K	﹤0.01%	580

Other funds holding PCRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

SCM

Spyglass Capital Management San Francisco, California $1.41B AUM 7.96% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

SIMG

Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return

Lee Financial's PCRX Position: Q1 2022 in Review

Lee Financial sold out of Pacira BioSciences (PCRX) in Q1 2022, closing a stake of 104 shares — an estimated $6K sold.

Lee Financial first reported a position in PCRX in Q4 2021 and held it in 1 quarter. The position peaked at $6K in Q4 2021. 301 funds tracked by Wall St. Rank hold PCRX as of Q1 2022.

Lee Financial reported no remaining Pacira BioSciences position as of Q1 2022 after selling out during the quarter.
Lee Financial sold 104 Pacira BioSciences shares in Q1 2022, an estimated $6K.
Lee Financial first reported a position in Pacira BioSciences in Q4 2021 and held it in 1 quarter.
Lee Financial's Pacira BioSciences position peaked at $6K in Q4 2021.
301 funds tracked by Wall St. Rank held Pacira BioSciences as of Q1 2022.

Based on Lee Financial's 13F filing for Q1 2022, filed 11 May 2022.